News

Podcast

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Author(s):

Alexandra Gerlach, Associate Editor

Explore the latest insights on emerging antibody drug conjugates for HER2 breast cancer and real-world management strategies.

In this episode of the Pharmacy Times Peer Exchange feature series about antibody drug conjugates (ADCs) and human epidermal growth factor receptor 2 (HER2) breast cancer (BC), oncology pharmacists discuss novel, emerging ADCs and real-world management of these therapies.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Pharmacy Times OPC
Related Content
Vials and syringe on white table with background windows - Image credit: Davizro Photography | stock.adobe.com
June 27th 2025

Zimislecel Could Pave the Way for a Type 1 Diabetes Cure

Kennedy Ferruggia, Assistant Editor
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
June 17th 2025

Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Pharmacist-Led Delabeling Protocol Aims to Determine Penicillin Allergies
June 25th 2025

Pharmacist-Led Delabeling Protocol Aims to Determine Penicillin Allergies

Aislinn Antrim, Managing Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Visualization of lungs with tumors | Image Credit: © Alexej - stock.adobe.com
June 25th 2025

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Alexandra Gerlach, Associate Editor
ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas
June 25th 2025

ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas

Jaume Capdevila, MD, PhD Alana Hippensteele, Lead Editor